About the Product

Description


Mirtafoam 7.5 Tablet contains Mirtazapine 7.5mg, a tetracyclic antidepressant commonly prescribed for major depressive disorder (MDD), anxiety, and related mood disorders. It enhances noradrenergic and serotonergic activity in the brain to improve mood, sleep, and overall mental well-being.

Belonging to the neurology and CNS segment, Mirtafoam 7.5 is recommended for patients experiencing persistent depressive symptoms, sleep disturbances, and anxiety, making it an essential prescription product for psychiatrists and general physicians.

The tablet promotes better adherence and tolerability, allowing gradual dose titration for improved patient outcomes. Its effectiveness in managing depression makes it a high-demand product in hospitals, mental health clinics, and retail pharmacies.

For PCD pharma franchise partners, wholesalers, exporters, and third-party manufacturers, Mirtafoam 7.5 Tablet offers a profitable B2B opportunity in the antidepressant market, with stable demand and strong growth potential across India.


Drowsiness, increased appetite, weight gain, dry mouth, dizziness, and mild gastrointestinal discomfort. Rarely, it may cause severe allergic reactions, low blood pressure, or changes in blood counts.

Used in the treatment of major depressive disorder (MDD), anxiety disorders, and sleep disturbances associated with depression. It helps improve mood, emotional stability, and overall daily functioning.

Take Mirtafoam 7.5 Tablet exactly as prescribed, preferably at bedtime. Do not stop suddenly. Inform your doctor if you have liver or kidney disease, a history of seizures, or are taking other antidepressant medications.

Store below 25°C in a cool, dry place away from sunlight and moisture. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Frequently Asked Questions

What are the business opportunities for Mirtazapine IP 7.5mg Tablet in the PCD pharma franchise market?

Mirtazapine IP 7.5mg Tablet has growing demand in the psychiatry, mental healthcare, and CNS (Central Nervous System) segment, making it a valuable product for medical distributors, wholesalers, and pharma franchise partners focusing on neuropsychiatric medicine portfolios.

Why should medical distributors include Mirtazapine IP 7.5mg Tablet in their product range?

Medical distributors and agencies can benefit from demand for mental health and mood disorder management under specialist supervision. Mirtazapine IP 7.5mg is an antidepressant medication used in psychiatric care Commonly prescribed for the management of depressive disorders and associated symptoms as advised by healthcare professionals Helps improve mood, emotional well-being, appetite, and overall quality of life in appropriate patients Lower-strength formulation provides flexibility for treatment initiation, dose titration, and individualized patient management Oral tablet formulation offers convenient administration for long-term therapy under medical supervision Requires regular monitoring and dosage adjustment based on patient response and clinical requirements Frequently utilized in psychiatry clinics, mental healthcare centers, hospitals, and specialty CNS care facilities Widely prescribed by psychiatrists and mental health specialists This strengthens a comprehensive psychiatry and CNS care portfolio.

Does Cafoli LifeCare Pvt Ltd offer PCD pharma franchise opportunities for this product?

Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Mirtazapine IP 7.5mg Tablet with promotional support, monopoly rights, attractive packaging, and competitive pricing for distributors and wholesalers.

What benefits do wholesalers get by partnering for this product?

Wholesalers and medical agencies benefit from consistent prescription demand, specialty healthcare market opportunities, repeat purchases, reliable supply chain support, and attractive margins in the neuropsychiatric segment.

How can I become a distributor or franchise partner for this product?

Interested distributors, stockists, and wholesalers can partner with Cafoli LifeCare Pvt Ltd to access lucrative PCD pharma franchise opportunities across India. With exclusive monopoly rights, extensive promotional support, high-quality pharmaceutical products, attractive business margins, and dependable logistics support, Cafoli LifeCare Pvt Ltd helps franchise partners build a successful and profitable pharmaceutical business.